Skip to content

Author

M. Camilli

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Sacubitril/valsartan in anthracycline-treated patients: a systematic review and meta-analysis of available evidence

Anthracyclines remain a cornerstone of systemic anticancer therapy but are limited by their well-recognized cardiotoxic potential, which may manifest as cancer therapy–related cardiac dysfunction (CTRCD). Despite increasing emphasis on preventive strategies in cardio-oncology, robust evidence supporting pharmacol...

M. Camilli, L. Spadafora · 0 citations
Aug 2026

Implementation of hfa-icos risk score in patients with non-hodgkin lymphoma undergoing non-pegylated doxorubicin therapy

Elderly patients with non-Hodgkin lymphoma, or patients with pre-existing cardiovascular comorbidities, are frequently treated with chemotherapy regimens containing non-PEGylated liposomal anthracycline, in order to reduce cardiotoxicity incidence. For patients candidate to anthracycline, the 2022 European Societ...

M. Camilli, I. Torre, L. Leo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.